1. Peptides
  2. HPV16 E7 (86-93) (TFA)

HPV16 E7 (86-93) (TFA) 

Cat. No.: HY-P1778A
Handling Instructions

HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

HPV16 E7 (86-93) (TFA) Chemical Structure

HPV16 E7 (86-93) (TFA) Chemical Structure

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Other Forms of HPV16 E7 (86-93) (TFA):

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas[1][2].

In Vitro

HPV16 E7 (86-93) specific T cells are expandable upon IVS (in vitro stimulation) with cognate peptide-pulsed dendritic cells (DCs) and are reactive against peptide-pulsed targets or, in case of the E711-20 epitope-specific T cells, against HPV16 E7 expressing CaSki cell line[1].
For peptide HPV16 E7 (86-93), the only response against K562 cells pulsed with the corresponding peptide was significantly blocked by anti-HLA class I Ab w6/32, which was not the case for HPV16 E7 expressing tumor cell line CaSki. Precursor T cells specific for HPV16 E7 (86-93) peptide is able to differentiate, at least in vitro, into HPVspecific effector cells[1].
HPV16 E7 peptide-loaded autologous dendritic cells (DCs) are able to stimulate a specific cytotoxic CD8+ T-cell response[2].

In Vivo

HPV16 E7 (86-93) peptide in IVS culture has specific T cell expansion. The HPV16 E7 (86-93) specific T cells produced does not recognize naturally HPV16 E7 expressing cell line CaSki. HPV16 E7 (86-93) peptides also has similar observations in transgenic mice. The HPV16 E7 (86-93) peptide is able to induce cytotoxic T lymphocyte (CTL) responses if loaded on the antigen presenting HLA class I molecules, but that the peptide appears not to be processed or presented by HPV16 infected cells[1].

Molecular Weight

929.06

Formula

C₃₉H₆₇F₃N₈O₁₂S

Sequence

Thr-Leu-Gly-Ile-Val-Cys-Pro-Ile

Sequence Shortening

TLGIVCPI

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

HPV16 E7 (86-93) (TFA)OthersImmunogeniccervicalcarcinomasHLA-A2cytotoxicCD8+T-cellInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product name:
HPV16 E7 (86-93) (TFA)
Cat. No.:
HY-P1778A
Quantity:
MCE Japan Authorized Agent: